Package of measures to combat symptom complexes – an update

In COPD, dual bronchodilation (LAMA/LABA) is generally considered the standard of care. If patients are prone to exacerbations, the addition of inhaled steroids (ICS) may be useful. But what about patients who achieve inadequate disease control despite these treatment options and who have an elevated blood eosinophil count (≥300 cells/µl)? For this subpopulation, dupilumab has been approved in the EU as an add-on, i.e. in addition to existing medication, since the end of June 2024.